title: Effect of anti-macrophage inflammatory protein-1alpha on leukocyte trafficking and disease progression in experimental autoimmune uveoretinitis.
abstract: This study has enabled us to identify the influence of the chemokine, macrophage inflammatory protein-1alpha (MIP-1alpha), on leukocyte behavior at the blood-retina barrier in vivo and its link with the inflammatory process and disease pathogenesis. MIP-1alpha has not previously been thought to be effective under conditions of physiological shear flow. However, short-term anti-MIP-1alpha treatment inhibited leukocyte slowing and accumulation and subsequent extravasation of leukocytes at the blood-retina barrier in animals with experimental autoimmune uveoretinitis. This was effective predominantly in the post-capillary venules which have been shown to be the main site of passage of leukocytes across the blood-retina barrier. Long-term anti-MIP-1alpha treatment also prevented decreased leukocyte velocity and reduced disease severity as measured clinically, histologically and in terms of blood-retina barrier breakdown.
authors.affiliation: Department of Ophthalmology, University of Aberdeen Medical School, Foresterhill, Aberdeen, GB. i.j.crane@abdn.ac.uk
authors.forename: Isabel J
authors.initials: IJ
authors.lastname: Crane
authors.forename: Heping
authors.initials: H
authors.lastname: Xu
authors.forename: Ayyakkannu
authors.initials: A
authors.lastname: Manivannan
authors.forename: Susan
authors.initials: S
authors.lastname: McKillop-Smith
authors.forename: Graeme
authors.initials: G
authors.lastname: Lamont
authors.forename: Carol
authors.initials: C
authors.lastname: Wallace
authors.forename: Janet
authors.initials: J
authors.lastname: Liversidge
authors.forename: Peter F
authors.initials: PF
authors.lastname: Sharp
authors.forename: John V
authors.initials: JV
authors.lastname: Forrester
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001327:Autoimmune Diseases / Q000276:immunology* / Q000503:physiopathology; D001813:Blood-Retinal Barrier; D002448:Cell Adhesion / Q000187:drug effects; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D018056:Hemorheology; D007834:Lasers; D036904:Leukocyte Rolling / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects* / Q000502:physiology; D019402:Macrophage Inflammatory Proteins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D051379:Mice; D018613:Microscopy, Confocal; D019721:Ophthalmoscopes; D009887:Ophthalmoscopy / Q000379:methods; D012173:Retinitis / Q000276:immunology* / Q000503:physiopathology; D014605:Uveitis / Q000276:immunology* / Q000503:physiopathology; D014699:Venules
chemical_list: D000911:Antibodies, Monoclonal; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D019402:Macrophage Inflammatory Proteins